As you set out for Ithaka hope the voyage is a long one, full of adventure, full of discovery.
C
oronary fibroatheromas can cause a wide spectrum of adverse events, such as sudden death, acute coronary syndromes, and procedural complications during percutaneous coronary interventions (PCI) (2) . Accurate fibroatheroma detection could significantly enhance our ability to treat these lesions and prevent complications. Grayscale IVUS, which is the oldest and most widely available intravascular imaging modality, was not developed specifically for the detection of fibroatheroma. However, IVUS-attenuated plaque (attenuation of the ultrasound beam in the absence of calcification), especially when superficial (closer to the lumen than the media), is a specific (but not sensitive) fibroatheroma "signature" (4, 5) .
Analysis of the backscattered radiofrequency IVUS signals (virtual histology IVUS and integrated backscatter IVUS) also allows plaque characterization, but it is challenging to perform in real time during the procedure because it requires accurate segmentation of the IVUS images, which is a time-consuming and labor-intensive process (3).
OCT identifies fibroatheromas as signal-poor regions with ill-defined borders (6), but OCT image interpretation is subjective and highly dependent on operator experience (3). Moreover, deep fibroatheromas may be harder to detect due to poor penetration of the near-infrared light beam.
NIRS was developed to specifically detect lipid core plaque in coronary arteries, on the basis of the specific chemical signature of the fibroatheroma (7).
Near-infrared light is directed to the coronary artery wall, and the reflected light is collected and analyzed using algorithms developed based on histological analyses (7) . NIRS is currently available as a com- What do these findings mean for everyday clinical practice? First, they confirm that superficial IVUS attenuation is a highly specific finding for fibroatheroma, which is especially important for centers that do not have the combined NIRS/IVUS system. Second, they demonstrate that the combined NIRS/ IVUS system has good performance characteristics for fibroatheroma detection, by allowing evaluation of both structure and composition.
FIBROATHEROMA DETECTED: NOW WHAT?
What to do after a fibroatheroma is detected during cardiac catheterization is a work in progress (Figure 1 ). Brilakis and Banerjee
use remains empiric and pre-supposes significant local expertise in complex coronary interventions and use of embolic protection devices. Moreover, use of embolic protection devices in native coronary arteries is off-label (they are only approved for use in saphenous vein grafts).
Third, fibroatheroma detection within a lesion treated with PCI may allow for optimal stent selection (13) . Using a long-enough stent to completely cover the fibroatheroma may reduce the rate of acute stent thrombosis (14) , and possibly restenosis. 
